“CoQ10 must be taken with statins”

the 2018 Mayo Clinic systematic review did not confirm clinical benefit. Russian and international cardiology societies do not include CoQ10 in statin-patient management standards.

“ubiquinol is the active form, much better than ubiquinone”

the bioavailability difference between ubiquinol and ubiquinone is substantially smaller than advertised. Ubiquinol costs 2–3 times more without proven clinical advantage for most patients.

ubidecarenone (coenzyme Q10)

Other cardiac preparations. Coenzyme Q10

ATC code: C01EB-COQ10 (Ubidecarenone (CoQ10) – local code)

Brand names – supplements

Nature's Bounty Co Q-10, Qunol Ultra CoQ10, Jarrow Formulas Ubiquinol QH-Absorb, Doctor's Best High Absorption CoQ10

Supplements are not tested in clinical trials and are not registered as medications.

Mechanism of action

Ubiquinone (CoQ10) is a component of the inner mitochondrial membrane electron transport chain, transferring electrons between complexes I/II and III. Required for ATP synthesis. An antioxidant: regenerates tocopherol and neutralises reactive oxygen species in membranes. Synthesised endogenously; levels decline with age and with statin therapy (via mevalonate pathway inhibition). Exists in two forms: oxidised (ubiquinone) and reduced (ubiquinol).

Indications

Primary coenzyme Q10 deficiency

First line

High-dose CoQ10 (10–30 mg/kg/day, in adults up to 1,200–2,400 mg daily) is the only disease-modifying approach to the rare inherited primary CoQ10 deficiency. Early therapy in children prevents progression of encephalopathy and nephrotic syndrome; in adults it stabilises cerebellar ataxia. GeneReviews and international mitochondrial disease guidelines support this use.

Used in specialised centres with confirmed genetic diagnosis; not for self-prescription.

Sources

GeneReviews: Primary Coenzyme Q10 Deficiency (2017)

Heart failure (adjunctive therapy)

Individual decision

The 2014 Q-SYMBIO trial (420 patients with NYHA II-IV HF) showed a 43% reduction in major cardiovascular events with CoQ10 100 mg three times daily. Cochrane 2021 rated the effect as promising but requiring confirmation in larger RCTs. International heart failure guidelines ( HF 2021, HF 2022) do not include CoQ10 in standard heart failure therapy.

Sources

Migraine prophylaxis

Not recommended

Evidence for CoQ10 in migraine prophylaxis is weak. 2012 and the 2019 paediatric update rate CoQ10 as level U (insufficient evidence to recommend for or against). The 2021 American Headache Society guideline does not include CoQ10 in first-line migraine prevention. Positive signals come from several small, methodologically weak RCTs (Sandor 2005, n=42; Rossi 2022 meta-analysis – limited methodology, partial manufacturer funding). No major independent RCTs exist, and no Cochrane review has been conducted. First-line migraine prophylaxis: beta-blockers, topiramate, CGRP antagonists.

Sources

AAN: Practice guideline update summary: Pharmacologic treatment for migraine prevention in children and adolescents (2019)

Statin-associated muscle symptoms

Not recommended

The 2018 Mayo Clinic systematic review (12 RCTs, 575 patients) found no clinically meaningful effect of CoQ10 on muscle pain intensity in statin-treated patients. The logic “statins reduce CoQ10 synthesis, so CoQ10 should help” is physiologically reasonable but not confirmed in controlled studies. and Russian cardiology guidelines do not recommend CoQ10 for statin-associated myalgia. Standard approach: switch molecule, reduce dose, intermittent dosing.

Sources

Mayo Clinic Proceedings: Coenzyme Q10 for statin-associated myopathy: a systematic review and meta-analysis of RCTs (2018)

Anti-aging, longevity, and quality-of-life enhancement in healthy adults

Not recommended

— Anti-aging and longevity: CoQ10 for slowing ageing and extending lifespan in healthy people lacks evidence. Age-related decline in CoQ10 levels is a physiological phenomenon whose link with lifespan has not been confirmed in large RCTs. The antioxidant hypothesis of ageing has not received compelling clinical support. International geriatric societies do not include CoQ10 in anti-ageing recommendations.

Sources

Cochrane: Coenzyme Q10 for heart failure (2021)

Practical notes

Timing and administration

Take with food, preferably one containing fat – CoQ10 is fat-soluble and absorption increases 2–3 fold with dietary fat. Divide the dose into 2–3 daily portions – large single doses are absorbed less efficiently.

Dose titration

Migraine prophylaxis: 100 mg three times daily. Heart failure: 100 mg three times daily (as in Q-SYMBIO). Primary CoQ10 deficiency: 10–30 mg/kg/day. Standard supplement doses of 30–60 mg daily roughly match age-related synthesis losses but are not clinically indicated for treatment.

Monitoring

No specific monitoring is needed during long-term therapy. In patients on warfarin, monitor INR when starting or stopping CoQ10 – modest reduction in anticoagulant effect is possible. In insulin-dependent diabetes, monitor glycaemia in the first weeks – reduced insulin requirements have been reported.

Food and drinks

Dietary CoQ10 sources: beef heart, beef, sardines, mackerel, peanuts. Average adult dietary intake is 3–6 mg daily, 10–30 times less than RCT doses. Endogenous synthesis is the main source. In statin-treated patients, plasma CoQ10 is 30–40% lower, but the clinical impact for most patients is minor.

Common myths

Myth: “everyone over 40 needs CoQ10”. Fact: age-related CoQ10 decline is physiological without proven clinical consequences in healthy people. Prophylactic “energy” use has not shown a wellbeing effect in RCTs.

Safety

Contraindications

Hypersensitivity to ubiquinone
Pregnancy (insufficient data)
Breastfeeding (insufficient data)
Children under 18 (for most supplement forms)

Serious adverse effects

Serious adverse events at standard doses are not reported

Common adverse effects

Nausea, heartburn
Epigastric discomfort
Headache

Uncommon adverse effects

Allergic reactions (rash, pruritus)
Insomnia, irritability with evening high-dose use

PregnancyFDA C

Pregnancy data are limited. In planned pregnancy and breastfeeding, use is not recommended without clear clinical indication.

Breastfeeding

No data on transfer into breast milk. Use during breastfeeding is not recommended.

Frequently asked

What is ubidecarenone (coenzyme Q10) used for?

ubidecarenone (coenzyme Q10) is evaluated for the following indications with varying evidence strength: Primary coenzyme Q10 deficiency (evidence tier A), Heart failure (adjunctive therapy) (evidence tier C), Statin-associated muscle symptoms (evidence tier D). See the full indication matrix with dosing and citations above on this page.

What are the side effects of ubidecarenone (coenzyme Q10)?

Common side effects of ubidecarenone (coenzyme Q10) (≥ 1 in 100): Nausea, heartburn, Epigastric discomfort, Headache. See the Safety section for uncommon and serious reactions.

Is ubidecarenone (coenzyme Q10) safe during pregnancy?

FDA category C. Pregnancy data are limited. In planned pregnancy and breastfeeding, use is not recommended without clear clinical indication.

Is ubidecarenone (coenzyme Q10) compatible with breastfeeding?

No data on transfer into breast milk. Use during breastfeeding is not recommended.

Who should not take ubidecarenone (coenzyme Q10)?

ubidecarenone (coenzyme Q10) is contraindicated in: Hypersensitivity to ubiquinone; Pregnancy (insufficient data); Breastfeeding (insufficient data); Children under 18 (for most supplement forms). Full list in the Safety section.